Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing immuno-oncology jargon, pipeline milestones, and dilution risks inside Werewolf Therapeutics’ SEC filings can feel like decoding lab notes. The company’s 10-K alone runs hundreds of pages on conditional IL-12 and IL-2 programs, cash runway assumptions, and collaboration clauses—details that are critical yet hard to spot.
Stock Titan’s AI-powered analysis turns that problem into a two-minute read. Our engine combs every Werewolf Therapeutics quarterly earnings report 10-Q filing, flags trial-phase updates, and highlights changes in R&D spend. Need to track management confidence? Real-time alerts surface Werewolf Therapeutics insider trading Form 4 transactions the moment they hit EDGAR. Curious about sudden stock moves? We translate each Werewolf Therapeutics 8-K material event into plain English, clarifying data-release language and financing announcements.
The result is one hub covering every document—from the annual report 10-K simplified for fast risk-factor review to proxy statement executive compensation details and executive stock transactions Form 4. Investors use these insights to monitor cash burn, compare quarter-over-quarter pipeline progress, and gauge insider sentiment before material catalysts. Stop wading through dense PDFs; understand Werewolf Therapeutics SEC filings explained simply with AI that keeps pace with biotech’s rapid developments.
PFM Health Sciences and related entities report owning 401,110 shares (0.9%) of Werewolf Therapeutics, Inc. (HOWL). The filing states that PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC and Brian D. Grossman may each be deemed to beneficially own 401,110 shares, representing 0.9% of the 44,873,646 shares outstanding used for the calculation. All reporting persons indicate no sole voting or dispositive power and 401,110 shares of shared voting and dispositive power. The statement clarifies the relationships among the entities and includes a certification that the securities were not acquired to influence control.
Werewolf Therapeutics (HOWL) reported continued clinical progress while managing a substantial cash burn. The company held $77.6 million of cash and cash equivalents and
The company advanced its lead programs: WTX-124 has a selected recommended dose and active monotherapy and combination expansion arms with interim data planned for the second half of 2025, and WTX-330 completed Phase 1 and initiated a Phase 1b/2 trial, dosing its first patient. Operating expense reductions versus prior year reflect lower manufacturing and R&D spend for select programs, partially offset by continued clinical and development costs.
Balance sheet and financing items include a $30.0 million term loan carrying a high effective interest cost (reported effective rate ~19.24%) with embedded conversion features and a derivative liability. Management states additional funding will be necessary beyond the 12-month runway to continue development activities.
Werewolf Therapeutics announced that it furnished a press release reporting its financial results for the quarter ended June 30, 2025, and that the press release is provided as Exhibit 99.1. The company also made an updated corporate investor presentation publicly available and furnished it as Exhibit 99.2. The filing specifies that these items are being furnished rather than filed under the Exchange Act and includes a standard cautionary note describing forward-looking statements and associated development, regulatory, and financing risks.
The 8-K does not include the financial figures within its text but notifies investors where the results and presentation are available as exhibits for review.
FAQ
What is the current stock price of Werewolf Therapeutics (HOWL)?
What is the market cap of Werewolf Therapeutics (HOWL)?
